Italy: Researchers have discovered in a new research that among patients with Hemophilia A , prophylaxis with Mim8 was superior to both on-demand therapy and clotting factor concentrate prophylaxis in reducing the annualized rate of treated bleeding events , regardless of inhibitor status.
Mim8 Prophylaxis Outperforms Other Treatments in Reducing Bleeding Episodes in Hemophilia A Patients
Medical Dialogues•
Full News
Share:
Disclaimer: This content has not been generated, created or edited by Achira News.
Publisher: Medical Dialogues
Want to join the conversation?
Download our mobile app to comment, share your thoughts, and interact with other readers.